IL102092A - Use of recombinant hiv envelope protein in medicament for treating hiv and therapeutic composition containing the agglomerated protein - Google Patents

Use of recombinant hiv envelope protein in medicament for treating hiv and therapeutic composition containing the agglomerated protein

Info

Publication number
IL102092A
IL102092A IL10209292A IL10209292A IL102092A IL 102092 A IL102092 A IL 102092A IL 10209292 A IL10209292 A IL 10209292A IL 10209292 A IL10209292 A IL 10209292A IL 102092 A IL102092 A IL 102092A
Authority
IL
Israel
Prior art keywords
gpl60
hiv
recombinant protein
recombinant
use according
Prior art date
Application number
IL10209292A
Other languages
English (en)
Other versions
IL102092A0 (en
Original Assignee
Microgenesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microgenesys Inc filed Critical Microgenesys Inc
Publication of IL102092A0 publication Critical patent/IL102092A0/xx
Publication of IL102092A publication Critical patent/IL102092A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL10209292A 1991-06-11 1992-06-03 Use of recombinant hiv envelope protein in medicament for treating hiv and therapeutic composition containing the agglomerated protein IL102092A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71415291A 1991-06-11 1991-06-11

Publications (2)

Publication Number Publication Date
IL102092A0 IL102092A0 (en) 1993-01-14
IL102092A true IL102092A (en) 1996-11-14

Family

ID=24868938

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10209292A IL102092A (en) 1991-06-11 1992-06-03 Use of recombinant hiv envelope protein in medicament for treating hiv and therapeutic composition containing the agglomerated protein

Country Status (18)

Country Link
EP (1) EP0542998A1 (ja)
JP (1) JPH06501851A (ja)
CN (1) CN1068266A (ja)
AU (2) AU2193192A (ja)
BG (1) BG97519A (ja)
CA (1) CA2087732A1 (ja)
EE (1) EE9400183A (ja)
FI (1) FI930577L (ja)
HU (1) HUT68355A (ja)
IE (1) IE921875A1 (ja)
IL (1) IL102092A (ja)
LT (1) LT3365B (ja)
MX (1) MX9202781A (ja)
PL (1) PL297849A1 (ja)
PT (1) PT100584A (ja)
SK (1) SK18993A3 (ja)
WO (1) WO1992022654A1 (ja)
ZA (1) ZA924150B (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40786E1 (en) * 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
CA2179394A1 (en) * 1993-12-23 1995-06-29 Kostas Iatrou Methods of expressing proteins in insect cells and methods of killing insects
US6475491B1 (en) 1995-06-07 2002-11-05 Trimeris, Inc. Treatment of HIV and other viral infections using combinatorial therapy
US6395541B1 (en) 1996-05-23 2002-05-28 The Rockefeller University Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US6077662A (en) * 1996-11-27 2000-06-20 Emory University Virus-like particles, methods and immunogenic compositions
US6214540B1 (en) 1997-03-26 2001-04-10 University Of Maryland Biotechnology Institute Chemokines that inhibit immunodeficiency virus infection and methods based thereon
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US6548631B1 (en) 1997-09-16 2003-04-15 BIOMéRIEUX, INC. Macrophage derived chemokine (MDC) as an anti-viral agent for the treatment and prevention of lentivirus infection
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
US6623741B1 (en) 2000-02-29 2003-09-23 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
AUPS065002A0 (en) 2002-02-20 2002-03-14 Immunaid Pty Ltd Strategy for retroviral immunotherapy
AU2003298912B2 (en) 2002-12-03 2011-06-02 Advanced Bioscience Laboratories, Inc. Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
DE602004030369D1 (de) 2003-10-24 2011-01-13 Immunaid Pty Ltd Therapieverfahren
GT200800303A (es) 2007-12-24 2009-09-18 Combinacion anti-retroviral
PL2435825T3 (pl) 2009-05-27 2015-12-31 Biotempus Ltd Sposoby leczenia chorób
EP2746394A4 (en) 2011-08-19 2015-07-15 Ostrich Pharma Kk ANTIBODY AND ANTIBODY COMPOSITION
CN102961760B (zh) * 2011-09-01 2017-07-18 常州文松生物技术有限公司 重叠肽作为制备皮肤试验和检测特异性细胞免疫的试剂及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1

Also Published As

Publication number Publication date
EE9400183A (et) 1995-12-15
JPH06501851A (ja) 1994-03-03
IL102092A0 (en) 1993-01-14
ZA924150B (en) 1993-02-24
CN1068266A (zh) 1993-01-27
IE921875A1 (en) 1992-12-16
HU9300686D0 (en) 1993-06-28
WO1992022654A1 (en) 1992-12-23
PT100584A (pt) 1993-07-30
MX9202781A (es) 1993-04-01
EP0542998A1 (en) 1993-05-26
AU2193192A (en) 1993-01-12
BG97519A (bg) 1994-03-24
FI930577A7 (fi) 1993-03-24
FI930577A0 (fi) 1993-02-10
SK18993A3 (en) 1993-10-06
CA2087732A1 (en) 1992-12-12
HUT68355A (en) 1995-06-28
PL297849A1 (en) 1994-01-24
FI930577L (fi) 1993-03-24
AU4028895A (en) 1996-02-22
LT3365B (en) 1995-07-25
LTIP335A (en) 1995-01-31

Similar Documents

Publication Publication Date Title
AU2193192A (en) Vaccine and treatment method of human immunodeficiency virus infection
AU732809B2 (en) Compositions and methods for treating viral infections
US5166050A (en) Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
EP0546787A2 (en) Expression of specific immunogens using viral antigens
AU7047894A (en) Hiv envelope polypeptides
IL127701A (en) HIV gp 120 ENVELOPE POLYPEPTIDES, VACCINE AND METHODS FOR THEIR PREPARATION
IE872219L (en) Treatment of hiv infections
EP0327180A2 (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
WO1989005821A1 (en) Hiv-related antigens and antibodies
US6290963B1 (en) Anti-HIV compositions containing native and recombinant peptides
LV10492B (en) Vaccine and treatment method for human immunodeficiency virus
AU2006200454B2 (en) Compositions and methods for treating viral infections
EP0784484A2 (en) Method of treatment of human immunodeficiency virus (hiv) infection
HRP921484A2 (en) Vaccine and treatment method of human immunodeficiency virus infection
SI9200420A (sl) Vakcina proti infekciji, ki jo povzroča človeški virus imunodeficience
LV10497B (en) A method for obtaining a vaccine comprising polypeptides derived from the HIV-1 virus envelope gene
HU211505A9 (hu) HIV-fertőzés kezelésére szolgáló vakcinakészítmény Az átmeneti oltalom az 1-15. igénypontokra vonatkozik.
AU2004201321A1 (en) Compositions and methods for treating viral infections
AU2006200455A1 (en) Compositions and methods for treating viral infections
AU2004208648A1 (en) Compositions and methods for treating infections

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees